Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development

Jayakrishna Ambati (), Joseph Magagnoli, Hannah Leung, Shao-bin Wang, Chris A. Andrews, Dongxu Fu, Akshat Pandey, Srabani Sahu, Siddharth Narendran, Shuichiro Hirahara, Shinichi Fukuda, Jian Sun, Lekha Pandya, Meenakshi Ambati, Felipe Pereira, Akhil Varshney, Tammy Cummings, James W. Hardin, Babatunde Edun, Charles L. Bennett, Kameshwari Ambati, Benjamin J. Fowler, Nagaraj Kerur, Christian Röver, Norbert Leitinger, Brian C. Werner, Joshua D. Stein, S. Scott Sutton and Bradley D. Gelfand
Additional contact information
Jayakrishna Ambati: University of Virginia School of Medicine
Joseph Magagnoli: Dorn Research Institute, Columbia VA Health Care System
Hannah Leung: University of Virginia School of Medicine
Shao-bin Wang: University of Virginia School of Medicine
Chris A. Andrews: University of Michigan Medical School
Dongxu Fu: University of Virginia School of Medicine
Akshat Pandey: University of Virginia School of Medicine
Srabani Sahu: University of Virginia School of Medicine
Siddharth Narendran: University of Virginia School of Medicine
Shuichiro Hirahara: University of Virginia School of Medicine
Shinichi Fukuda: University of Virginia School of Medicine
Jian Sun: University of Virginia School of Medicine
Lekha Pandya: University of Virginia School of Medicine
Meenakshi Ambati: University of Virginia School of Medicine
Felipe Pereira: University of Virginia School of Medicine
Akhil Varshney: University of Virginia School of Medicine
Tammy Cummings: Dorn Research Institute, Columbia VA Health Care System
James W. Hardin: University of South Carolina
Babatunde Edun: Dorn Research Institute, Columbia VA Health Care System
Charles L. Bennett: Dorn Research Institute, Columbia VA Health Care System
Kameshwari Ambati: University of Virginia School of Medicine
Benjamin J. Fowler: University of Kentucky
Nagaraj Kerur: University of Virginia School of Medicine
Christian Röver: University Medical Center Göttingen
Norbert Leitinger: University of Virginia School of Medicine
Brian C. Werner: University of Virginia School of Medicine
Joshua D. Stein: University of South Carolina
S. Scott Sutton: Dorn Research Institute, Columbia VA Health Care System
Bradley D. Gelfand: University of Virginia School of Medicine

Nature Communications, 2020, vol. 11, issue 1, 1-12

Abstract: Abstract Innate immune signaling through the NLRP3 inflammasome is activated by multiple diabetes-related stressors, but whether targeting the inflammasome is beneficial for diabetes is still unclear. Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activation. Here, we show, by analyzing five health insurance databases, that the adjusted risk of incident diabetes is 33% lower in patients with NRTI exposure among 128,861 patients with HIV-1 or hepatitis B (adjusted hazard ratio for NRTI exposure, 0.673; 95% confidence interval, 0.638 to 0.710; P

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18528-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18528-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18528-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().